After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic versions of Novo Nordisk’s lucrative semaglutide drugs for diabetes and obesi | ...

Women and older adults using semaglutide, a popular anti-obesity medication, may face a heightened risk of muscle loss. A recent study suggests that women and older adults who use the weight-loss drug ...

Longer treatment duration, not having diabetes, and using semaglutide are among the factors linked to better weight reduction over 12 months.

Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.

What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Researchers says the drugs could be a treatment for obese people with asthma who are ‘often resistant’ to steroids ...

GLP-1 blockbusters like semaglutide and tirzepatide are widely used for diabetes and weight loss but come with some nasty ...

Before you go, check out Dr. Lawrence Rosenberg's reflection on what "excellence" actually means in health care. He is the ...

An NHS surgeon has delivered his 'hot take' on why weight-loss jabs like Wegovy and Mounjaro are causing 'Ozempic babies' to be born.